Clinical Scorecard: Exploring AI's Role as a Mechanistic Tool and Digital Replica in Colorectal Cancer Immunotherapy

At a Glance

Key Highlights

• AI can decode tumor-immune biology from multimodal data.
• AI serves as a digital twin for individualized therapeutic modeling.
• Current biomarkers provide static snapshots of tumor-immune interactions.
• AI enhances pathology, imaging, and liquid biopsy for treatment stratification.
• AI may facilitate cold-to-hot tumor transitions and adaptive trial designs.

Guideline-Based Recommendations

Diagnosis

• Utilize AI to predict microsatellite instability (MSI) and mismatch repair deficiency (dMMR) from histology.

Management

• Integrate AI-driven models for dynamic simulation of treatment response and resistance.

Monitoring & Follow-up

• Employ AI-enhanced analysis of circulating tumor DNA (ctDNA) for monitoring minimal residual disease.

Risks

• Address challenges in generalizability, interpretability, and regulatory validation of AI tools.

Patient & Prescribing Data

Patients with advanced colorectal cancer, particularly those with MSI-H or dMMR tumors.

AI can inform treatment decisions by modeling patient-specific therapeutic trajectories.

Clinical Best Practices

• Use multimodal data to enhance understanding of tumor-immune interactions.
• Incorporate AI tools in clinical trials to adaptively design studies based on real-time data.
• Focus on integrating AI insights into routine clinical practice for personalized treatment approaches.

Related Resources & Content

• Colorectal Cancer Statistics
• AI in Cancer Immunotherapy